Au KP, Chiang CL, Chan ACY, Cheung TT, Lo CM, Chok KSH. Initial experience with stereotactic body radiotherapy for intrahepatic hepatocellular carcinoma recurrence after liver transplantation. World J Clin Cases 2020; 8(13): 2758-2768 [PMID: 32742986 DOI: 10.12998/wjcc.v8.i13.2758]
Corresponding Author of This Article
Kenneth Siu Ho Chok, FACS, FRCS (Ed), MBBS, Associate Professor, Department of Surgery, Queen Mary Hospital, The University of Hong Kong, 102 Pokfulam Road, Hong Kong 999077, China. chok6275@hku.hk
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jul 6, 2020; 8(13): 2758-2768 Published online Jul 6, 2020. doi: 10.12998/wjcc.v8.i13.2758
Initial experience with stereotactic body radiotherapy for intrahepatic hepatocellular carcinoma recurrence after liver transplantation
Kin Pan Au, Chi Leung Chiang, Albert Chi Yan Chan, Tan To Cheung, Chung Mau Lo, Kenneth Siu Ho Chok
Kin Pan Au, Albert Chi Yan Chan, Tan To Cheung, Chung Mau Lo, Kenneth Siu Ho Chok, Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong 999077, China
Chi Leung Chiang, Department of Clinical Oncology, Queen Mary Hospital, the University of Hong Kong, Hong Kong 999077, China
Author contributions: Chok KSH designed this study; Au KP and Chiang CL conducted the study, analyzed the data and wrote the manuscript; Chan ACY, Cheung TT and Lo CM reviewed and provided supervision.
Institutional review board statement: This study was reviewed and approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster.
Informed consent statement: All patients have signed the informed consent form.
Conflict-of-interest statement: We have no financial relationships to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Kenneth Siu Ho Chok, FACS, FRCS (Ed), MBBS, Associate Professor, Department of Surgery, Queen Mary Hospital, The University of Hong Kong, 102 Pokfulam Road, Hong Kong 999077, China. chok6275@hku.hk
Received: November 13, 2019 Peer-review started: November 13, 2019 First decision: March 15, 2020 Revised: May 14, 2020 Accepted: May 19, 2020 Article in press: May 19, 2020 Published online: July 6, 2020
ARTICLE HIGHLIGHTS
Research background
Graft hepatocellular carcinoma (HCC) recurrence after liver transplant is not uncommon. Graft hepatectomy is technically challenging and is associated with high morbidity. Stereotactic body radiation therapy (SBRT) could be a safe alternative treatment modality to graft HCC recurrence.
Research motivation
The role of SBRT for HCC recurrence in a liver graft remains unclear.
Research objectives
The current study aims to evaluate the safety and efficacy of SBRT for graft HCC recurrence after liver transplantation.
Research methods
A retrospective study of 6 patients and 9 treatment courses for 13 recurrent tumours in the liver graft.
Research results
Five patient had complete local response (55%). The median time to overall disease progression was 6.5 mo. There were 6 regional progression in the liver graft (67%). There was no grade 3 or above toxicity.
Research conclusions
SBRT appears safe but regional progression is common.
Research perspectives
The role of SBRT combined with additional regional treatment could be explored.
